Show simple item record

dc.contributor.authorLegros, D
dc.contributor.authorPaquet, C
dc.contributor.authorPerea, W
dc.contributor.authorMarty, I
dc.contributor.authorMugisha, N K
dc.contributor.authorRoyer, H
dc.contributor.authorNeira, M
dc.contributor.authorIvanoff, B
dc.date.accessioned2008-02-21T12:56:44Z
dc.date.available2008-02-21T12:56:44Z
dc.date.issued1999
dc.identifier.citationMass Vaccination with a Two-Dose Oral Cholera Vaccine in a Refugee Camp. 1999, 77 (10):837-42 Bull. World Health Organ.en
dc.identifier.issn0042-9686
dc.identifier.pmid10593032
dc.identifier.urihttp://hdl.handle.net/10144/18815
dc.description.abstractIn refugee settings, the use of cholera vaccines is controversial since a mass vaccination campaign might disrupt other priority interventions. We therefore conducted a study to assess the feasibility of such a campaign using a two-dose oral cholera vaccine in a refugee camp. The campaign, using killed whole-cell/recombinant B-subunit cholera vaccine, was carried out in October 1997 among 44,000 south Sudanese refugees in Uganda. Outcome variables included the number of doses administered, the drop-out rate between the two rounds, the proportion of vaccine wasted, the speed of administration, the cost of the campaign, and the vaccine coverage. Overall, 63,220 doses of vaccine were administered. At best, 200 vaccine doses were administered per vaccination site and per hour. The direct cost of the campaign amounted to US$ 14,655, not including the vaccine itself. Vaccine coverage, based on vaccination cards, was 83.0% and 75.9% for the first and second rounds, respectively. Mass vaccination of a large refugee population with an oral cholera vaccine therefore proved to be feasible. A pre-emptive vaccination strategy could be considered in stable refugee settings and in urban slums in high-risk areas. However, the potential cost of the vaccine and the absence of quickly accessible stockpiles are major drawbacks for its large-scale use.
dc.language.isoenen
dc.publisherPublished by WHO
dc.relation.urlhttp://www.who.int/bulletin/en
dc.rightsArchived on this site with permission of WHOen
dc.subject.meshAdministration, Oralen
dc.subject.meshAdolescenten
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshCholeraen
dc.subject.meshCholera Vaccinesen
dc.subject.meshDirect Service Costsen
dc.subject.meshFeasibility Studiesen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshMaleen
dc.subject.meshPatient Acceptance of Health Careen
dc.subject.meshProgram Evaluationen
dc.subject.meshRefugeesen
dc.subject.meshSudanen
dc.subject.meshUgandaen
dc.subject.meshVaccinationen
dc.titleMass Vaccination with a Two-Dose Oral Cholera Vaccine in a Refugee Camp.en
dc.contributor.departmentEpicentre, Kampala, Uganda.en
dc.identifier.journalBulletin of the World Health Organizationen
refterms.dateFOA2019-03-04T09:27:14Z
html.description.abstractIn refugee settings, the use of cholera vaccines is controversial since a mass vaccination campaign might disrupt other priority interventions. We therefore conducted a study to assess the feasibility of such a campaign using a two-dose oral cholera vaccine in a refugee camp. The campaign, using killed whole-cell/recombinant B-subunit cholera vaccine, was carried out in October 1997 among 44,000 south Sudanese refugees in Uganda. Outcome variables included the number of doses administered, the drop-out rate between the two rounds, the proportion of vaccine wasted, the speed of administration, the cost of the campaign, and the vaccine coverage. Overall, 63,220 doses of vaccine were administered. At best, 200 vaccine doses were administered per vaccination site and per hour. The direct cost of the campaign amounted to US$ 14,655, not including the vaccine itself. Vaccine coverage, based on vaccination cards, was 83.0% and 75.9% for the first and second rounds, respectively. Mass vaccination of a large refugee population with an oral cholera vaccine therefore proved to be feasible. A pre-emptive vaccination strategy could be considered in stable refugee settings and in urban slums in high-risk areas. However, the potential cost of the vaccine and the absence of quickly accessible stockpiles are major drawbacks for its large-scale use.


Files in this item

Thumbnail
Name:
vaccination.pdf
Size:
94Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record